Last reviewed · How we verify
Aromatase inhibitor and GnRH analog — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Aromatase inhibitor and GnRH analog (Aromatase inhibitor and GnRH analog) — Centre for Endocrinology and Reproductive Medicine, Italy.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Aromatase inhibitor and GnRH analog TARGET | Aromatase inhibitor and GnRH analog | Centre for Endocrinology and Reproductive Medicine, Italy | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Aromatase inhibitor and GnRH analog CI watch — RSS
- Aromatase inhibitor and GnRH analog CI watch — Atom
- Aromatase inhibitor and GnRH analog CI watch — JSON
- Aromatase inhibitor and GnRH analog alone — RSS
Cite this brief
Drug Landscape (2026). Aromatase inhibitor and GnRH analog — Competitive Intelligence Brief. https://druglandscape.com/ci/aromatase-inhibitor-and-gnrh-analog. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab